leadf
logo-loader
viewUrigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

Urigen Pharmaceuticals, Inc CEO Dan Vickery sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The privately-held company specializes in non-oncological urology treatments.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

K2fly welcomes new five-year SaaS deal with Coeur Mining

K2fly Ltd's (ASX:K2F) Nic Pollock caught up with Proactive's Andrew Scott following the news they've signed a five-year resource inventory management software as a service contract with New York Stock Exchange-listed precious metals mining company Coeur Mining Inc (NYSE:CDE) (FRA:CDM1). This...

1 hour, 4 minutes ago

2 min read